SelectScience
Join Free
Accelerating Science
NewsLife Sciences

Discover How Researchers at Rush Medical Center are Developing Novel Diagnostic Tests for Non-Small Cell Lung Cancer

SelectScience

Guest Editor, Yasha Talaga of MilliporeSigma, spoke to lead scientist, Dr Jeffrey Borgia to find out more

16 Jan 2017
Lynsey Forsyth
Post Doc / Research Fellow

Editorial article

Yasha Talaga, MilliporeSigma

Dr. Jeffrey A. Borgia, an Associate Professor at Rush University Medical Center spoke about his latest research. The lab is focused on the development of novel diagnostic tests to help guide treatment decisions for patients with non-small cell lung cancer. Currently, Dr. Borgia is refining his companion biomarker panel that will serve as a companion test for lung cancer screening.

His lab has preliminarily developed a companion diagnostic test for risk-stratifying individuals at high risk for lung cancer and a positive. His test is based on “multiple analyses and performed using the Luminex® platform. Its main strength is its high negative predictive value, which is an attractive means to help reduce the large numbers of false positives resulting from CT based lung cancer screening protocols,” explains Dr. Borgia. His group is trying to create more effective screening protocols which will reduce the mortality statics in the near future.

Dr. Jeffrey A. Borgia, Associate Professor at Rush University Medical Center

Biomarkers in discovery

This assay is being developed on the Luminex® platform using a wide array of excellent commercially available kits from MilliporeSigma and other sources. The proteomic capabilities of Dr. Borgia’s group enables custom assays to also be developed. As Dr. Borgia explains, “We recently reported great performance increases in our panel by integrating biomarkers from the Milliplex® Map human circulating angiogenesis panels.” These MilliporeSigma biomarkers are helpful “given that angiogenesis is one of the central cancer hallmarks. This made very sound logical sense that these biomarkers had diagnostic value,” notes Dr. Borgia.

Future perspectives

Following the establishment of a novel candidate biomarker, Dr. Borgia plans to “improve our ability to identify which patients with screen-detected tumors have a particularly aggressive pathology that would benefit from adjuvant treatment strategies usually reserved for more advanced tumors. With this, we expect to provide even more survival benefit for the patients from having their lung cancer detected early by the emerging screening protocols. The goal is to make lung cancer a manageable disease that no longer carries the grim statistics it currently does.” The biomarker panels being evaluated include the commercially-available biomarkers from MilliporeSigma that are surrogates for multiple biological pathways implicated in tumorigenesis and metastatic progression.

Do you use Milliplex® Map panels? Share your expertise and write a review today.

Related products

Request Quote for All Products

MILLIPLEX MAP Human Complement Panel 1 - Immunology Multiplex Assay

Merck

EMD Millipore’s MILLIPLEX® MAP Complement Panel 1 Magnetic Bead Panel is an 8-plex kit to be used for the simultaneous quantification of any or all of the following analytes in serum, plasma or culture supernatant samples: Complement 2, Complement C4B, Complement C5, Complement C5a, Complement C9, Adipson/Complement Factor D, Mannose-Binding Lecting (MBL) and Complement Factor I. MILLIPLEX® MAP offers the broadest selection of analytes across a wide range of disease states and species. Once the analytes of interest have been identified, you can rely on the quality that we build into each kit to produce results you can trust. In addition to the assay characteristics listed in the protocol, other performance criteria evaluated during the validation process include: cross-reactivity, dilution linearity, kit stability, and sample behavior(e.g. detectability and stability). Each panel and kit meets stringent manufacturing criteria to ensure batch-to-batch reproducibility. Each MILLIPLEX® MAP panel and kit includes: Quality controls (QCs) provided to qualify assay performance Comparison of standard (calibrator) and QC lots to a reference lot to ensure lot-to-lot consistency Optimized serum matrix to mimic native analyte environment Detection antibody cocktails designed to yield consistent analyte profiles within panel EMD Millipore’s MILLIPLEX® MAP Complement Panel 1 Magnetic Bead Panel is part of the most versatile system available for complement factor research. From our single to multiplex biomarker solutions, we partner with you to design, develop, analytically validate and build the most comprehensive library available for protein detection and quantitation.

(0)

Links

SelectScienceCompany website

Tags

ELISAEnzyme-linked immunosorbent assays (ELISA), also known as enzyme immunoassays (EIA), are used for the detection and quantification of proteins, peptides and antibodies in a sample. ELISA often comes in kit format, with pre-selected antibody pairs to detect specific proteins or biomarkers of diseases such as diabetes and obesity, or cardiovascular and neurological disorders. Detection is made possible with chemiluminescent, fluorescent or colorimetric substrates and detection instruments such as microplate / ELISA readers. Other kits available include: Enzyme-linked immunospot (ELISPOT) assays for the quantification of protein-producing cells and chemiluminescent immunoassays (CLIA) kits. Find the best ELISA kits and products in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.Cell-Based AssaysCell-based assays are used to monitor the presence, quantity and activities of a desired cellular analyte including drug molecules or biomarkers. This can reveal information on cell health (apoptosis, cytotoxicity, viability and proliferation assays), cell metabolism, cell migration and cell signaling mechanisms. Find the best cell-based assay products, kits and equipment with our peer reviewed product directory: compare products, check customer reviews and receiving pricing direct from manufacturers.Point-of-CarePoint-of-Care Testing (POCT) or Near Patient Testing (NPT) products are available for urine, blood and other clinical chemistry analyses. POCT includes: blood glucose testing, blood gas and electrolytes analysis, rapid coagulation testing (PT / INR), rapid cardiac markers diagnostics, drugs of abuse screening, urine strips testing, pregnancy testing, fecal occult blood analysis, food pathogens screening, hemoglobin diagnostics, infectious disease testing and cholesterol screening.Cancer DiagnosticsThere are a wide variety of diagnostic tests for cancer available, and this range continues to expand as our knowledge of cancer improves. Current diagnostic methods include biopsy, imaging and blood tests for known biomarkers. New methods in research development include liquid biopsies and cancer breathalyzers.Lung CancerLung cancer is a leading cause of cancer-related deaths worldwide, often diagnosed at an advanced stage. Research focuses on early detection, targeted therapies, and personalized treatment strategies. Explore lung cancer research and diagnostic products in our peer-reviewed product directory; compare products, check reviews, and get pricing directly from manufacturers.Cancer ResearchCancer research aims to understand the mechanisms of cancer development and progression to improve prevention, diagnosis, and treatment. From molecular biology to clinical trials, research spans a wide range of disciplines, including immunotherapy, targeted therapies, and drug discovery. Explore the best cancer research products in our peer-reviewed product directory; compare products, check reviews, and get pricing directly from manufacturers.Assay DevelopmentThe process of proving an assay to be sensitive with respect to the target is known as assay development. The assay should be able to characterize novel compounds and measure the potency of these compounds against a validated biological target.Biomarker DiscoveryClinical biomarkers refer to substances related to known medical conditions that can be accurately measured <i>in vitro</i>. Biomarkers can be used to diagnose presence of a disease and indicate disease severity. The discovery of new biomarkers is incredibly valuable in the field of diagnostics.

Related articles